Vascular graft thrombosis is one of the most significant complications following vascular surgery, where a blood clot forms inside an artificial blood vessel or graft, blocking blood flow and potentially undoing the benefits of the surgical procedure. Understanding the causes, treatment approaches, and prevention strategies is crucial for both patients and healthcare providers dealing with this challenging condition.

When Blood Flow Stops: The Challenge of Treatment Goals

The treatment of vascular graft thrombosis focuses on restoring blood flow through the blocked graft and preventing future clotting episodes. The main goal is to remove the blood clot quickly enough to save the graft and restore its function, whether that graft is providing dialysis access, bypassing diseased arteries, or replacing damaged blood vessels. Treatment success depends heavily on how soon the thrombosis is detected and addressed, as well as the underlying cause of the clot formation.^[2]

The approach to treating a thrombosed graft varies depending on several important factors. These include the type of graft material used—whether synthetic materials like expanded polytetrafluoroethylene (ePTFE) (also known as expanded Teflon) or Dacron fabric, or natural tissue like saphenous vein grafts. The location of the graft in the body also matters significantly, as does the time that has passed since the clot formed. Treatment must also take into account the patient’s overall health condition, including any bleeding disorders or other medical problems that might affect healing.^[1]

Medical professionals follow established guidelines that recommend different treatment strategies based on whether the thrombosis occurred early after surgery (within the first month), at an intermediate timepoint (between one month and two years), or late (more than two years after the initial surgery). Each timeframe typically points to different underlying causes, which in turn influences the choice of treatment. Early failures often result from technical issues during surgery, intermediate failures from tissue overgrowth at connection points, and late failures from disease progression in the blood vessels themselves.^[5]

Standard Treatment Approaches for Graft Thrombosis

The traditional approach to treating a thrombosed vascular graft involves either surgical removal of the clot or minimally invasive endovascular procedures. Surgical thrombectomy, which means removing the clot through an incision, has been used for many decades. During this procedure, the surgeon makes an incision over the affected graft and uses specialized balloon catheters to extract the clot from both the arterial and venous sides of the graft. This approach typically requires general anesthesia, which can be challenging for patients with multiple health problems, a common situation among those needing vascular grafts.^[12]

Endovascular or percutaneous approaches have become increasingly popular because they are less invasive. These procedures involve accessing the thrombosed graft through needle punctures rather than large incisions. A common endovascular method is mechanical thrombectomy, where specialized devices are inserted into the graft to break up and remove the clot. One frequently used device is the percutaneous thrombectomy device, which mechanically disrupts the clot so it can be removed through aspiration or dissolved by the body’s natural clot-breaking systems.^[2]

Manual aspiration thrombectomy is another endovascular technique where physicians use guiding catheters to directly suction out the clot material. This method can be effective for fresh clots and has been successfully used to treat arterial graft thrombosis in various locations. The technique requires skill to navigate the catheters through the graft without causing damage or pushing clot material into other blood vessels.^[7]

An essential part of treating arteriovenous graft thrombosis, particularly for dialysis access grafts, involves addressing the arterial plug—a clot that forms at the connection point between the artery and the graft. This plug appears in essentially 100% of graft thrombosis cases. It must be removed to restore blood flow, typically using specialized devices or compliant balloon catheters. The removal must be done carefully to minimize the risk of pushing clot material into the arm arteries, which occurs in about 5% of procedures but can often be managed if it happens.^[2]

After successfully removing the clot, physicians must address the underlying problem that caused the thrombosis. The most common culprit is intimal hyperplasia, an abnormal thickening of the vessel lining that narrows the channel where blood flows. This typically occurs at the point where the graft connects to the vein, called the venous anastomosis. Treatment involves using balloon angioplasty to widen the narrowed area by inflating a balloon inside the vessel to stretch it open.^[2]

When balloon angioplasty alone doesn’t provide lasting results, physicians may use stent grafts—tubular mesh devices that prop open the narrowed segment. Clinical studies have shown that certain stent grafts with special coatings can reduce the number of repeat procedures needed. In one study, grafts treated with a particular stent graft device showed a 40% reduction in the mean number of interventions needed over two years compared to balloon angioplasty alone for thrombosed grafts.^[4]

The duration of treatment extends beyond the immediate procedure to remove the clot. Patients typically require ongoing monitoring to watch for signs of repeat thrombosis or new narrowing. This may involve regular physical examination of the graft, checking for the characteristic vibration or “thrill” that indicates good blood flow, and listening with a stethoscope for the rushing sound or “bruit” of blood moving through the graft. Some patients may need periodic angioplasty procedures—on average two to three times per year—to maintain graft function even after successful treatment of thrombosis.^[4]

Medication plays a supporting role in standard treatment. Heparin, a blood-thinning medication, is commonly administered during thrombectomy procedures to prevent new clot formation while the physicians work. The decision about whether to continue blood-thinning medications long-term depends on individual patient factors and the type of graft involved.^[4]

Side effects and complications of standard thrombectomy procedures include the risk of arterial embolization, where pieces of clot break off and travel into smaller arteries. This complication is often related to pressurizing the graft through flushing or contrast injection before the clot is completely removed, rather than from the clot removal itself. Other risks include bleeding at access sites, damage to the graft or connected blood vessels, and infection. Despite these risks, endovascular procedures generally have high technical success rates, though the long-term patency—meaning the graft stays open—remains a challenge.^[2]

Innovative Treatments Being Studied in Clinical Trials

While clinical trial information specifically focused on preventing or treating vascular graft thrombosis is limited in the provided sources, one interesting case report describes the use of a novel oral anticoagulant medication to treat a specific type of graft thrombosis. A patient with saphenous vein graft thrombosis following coronary artery bypass surgery was treated with rivaroxaban, a medication that blocks certain clotting factors in the blood. This represents an innovative approach because it avoids the need for high-risk interventional procedures.^[9]

In this particular case, the patient’s thrombosis was believed to be caused by an outflow mismatch—meaning the large saphenous vein graft was connected to a smaller native artery, creating sluggish blood flow and stasis that promoted clot formation. Rather than performing a percutaneous coronary intervention, which carries high risk for dislodging clot material that could travel downstream, the medical team prescribed rivaroxaban at a dose of 20 milligrams once daily. Follow-up imaging four weeks after starting the medication showed complete resolution of the blood clot.^[9]

This case suggests that rivaroxaban could potentially become a treatment option for graft thrombosis caused by stasis or slow blood flow, particularly in situations where mechanical clot removal carries high risk. The medication works by inhibiting Factor Xa, a key protein in the blood clotting cascade, thereby preventing new clot formation and potentially allowing the body’s natural clot-dissolving mechanisms to clear existing clots. However, this approach has only been described in isolated case reports and would need systematic study in clinical trials to determine its effectiveness and safety across broader patient populations.^[9]

Research into improving vascular graft design itself represents another area of innovation aimed at preventing thrombosis before it occurs. Scientists are investigating advanced surface coatings that make synthetic grafts more hemocompatible, meaning less likely to trigger blood clotting. These bio-inspired coatings aim to mimic the natural non-stick properties of healthy blood vessel linings. By reducing platelet adhesion and dampening clot formation, such coatings could improve the long-term success of synthetic grafts, particularly the smaller-diameter grafts that currently have very high failure rates.^[11]

Tissue engineering approaches are also under investigation, where researchers are developing grafts that incorporate living cells or biological materials that encourage the patient’s own cells to grow into the graft. The goal is to create grafts that heal more like natural tissue with proper blood vessel formation (vascularization) rather than forming dense scar tissue (fibrotic encapsulation) that can lead to narrowing and thrombosis. While hundreds of research papers have been published on small-diameter vascular grafts, regulatory approval of truly successful small-diameter synthetic or bioengineered grafts remains elusive.^[1]

Another area of innovation involves addressing the mechanical mismatch between synthetic grafts and natural blood vessels. Synthetic materials like ePTFE and Dacron have different stiffness properties compared to native arteries, which can create disturbed blood flow patterns at connection points. This mechanical mismatch contributes to intimal hyperplasia—the excessive cell growth that narrows grafts over time. Researchers are working on developing grafts with compliance (flexibility) more similar to native vessels while maintaining structural durability, though achieving this balance remains a significant technical challenge.^[11]

Some studies are exploring whether certain medications given before and after graft placement could prevent thrombosis. While specific clinical trial details are not provided in the sources, the concept of optimal medical therapy before and after vascular procedures is recognized as having strong evidence for optimizing graft survival. This likely includes medications to control cholesterol, blood pressure, and potentially blood thinning agents, though the exact protocols continue to be refined through ongoing research.^[16]

Most Common Treatment Methods

• Mechanical Thrombectomy
  • Percutaneous thrombectomy devices that mechanically disrupt blood clots inside the graft using rotating elements or other mechanisms
  • Manual aspiration thrombectomy using guiding catheters to suction out clot material directly
  • Fogarty balloon catheters used to extract clots from both arterial and venous portions of the graft
  • Treatment of arterial plugs at the connection points using specialized devices or compliant balloons
• Surgical Thrombectomy
  • Open surgical approach involving incision over the graft to directly access and remove clot material
  • Use of embolectomy catheters to clear clots from venous and arterial aspects of the fistula
  • Typically requires general anesthesia and may be preferred for complex cases or mega-fistula thromboses
• Balloon Angioplasty
  • Widening of narrowed areas, particularly at venous anastomosis sites, using inflatable balloon catheters
  • Treatment of intimal hyperplasia that commonly causes intermediate and late graft failures
  • Often performed after clot removal to address the underlying cause of thrombosis
• Stent Graft Placement
  • Tubular mesh devices placed at narrowed segments to maintain vessel opening
  • Special stent grafts with heparin-coated surfaces that may reduce the need for repeat interventions
  • Particularly useful for managing venous anastomosis stenosis in recurrent thrombosis cases
  • Studies show potential for 40% reduction in intervention frequency over two years compared to balloon angioplasty alone
• Anticoagulation Therapy
  • Heparin administered during thrombectomy procedures to prevent new clot formation
  • Novel oral anticoagulants like rivaroxaban being explored for specific cases of graft thrombosis due to flow mismatch
  • Potential for complete clot resolution with oral medication in selected cases, avoiding need for mechanical intervention